{"id":410135,"date":"2024-10-20T05:38:58","date_gmt":"2024-10-20T05:38:58","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/bsi-pd-iso-tr-12417-22022-2\/"},"modified":"2024-10-26T10:23:17","modified_gmt":"2024-10-26T10:23:17","slug":"bsi-pd-iso-tr-12417-22022-2","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/bsi\/bsi-pd-iso-tr-12417-22022-2\/","title":{"rendered":"BSI PD ISO\/TR 12417-2:2022"},"content":{"rendered":"
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
2<\/td>\n | undefined <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
9<\/td>\n | 1 Scope 2 Normative references 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
12<\/td>\n | 4 Information on device- and drug-related aspects \u2014 Applicable documents for local guidance 4.1 General 4.2 Australia 4.2.1 General <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | 4.2.2 Australia: Managing changes 4.2.3 Australia: Clinical evaluation requirements 4.2.4 Australia: Audit requirements 4.3 Brazil 4.3.1 Brazil: Managing changes <\/td>\n<\/tr>\n | ||||||
14<\/td>\n | 4.3.2 Brazil: Clinical evaluation requirements 4.3.3 Brazil: Audit requirements 4.4 Canada 4.4.1 Canada: Managing changes 4.4.2 Canada: Clinical evaluation requirements 4.4.3 Canada: Audit requirements 4.5 European Union (EU) 4.5.1 EU: Managing changes <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 4.5.2 EU: Material inclusion and labelling requirements 4.5.3 EU: Clinical evaluation requirements 4.5.4 EU: Audit requirements 4.6 India 4.6.1 India: Managing changes <\/td>\n<\/tr>\n | ||||||
16<\/td>\n | 4.6.2 India: Clinical evaluation requirements 4.6.3 India: Audit requirements 4.7 Japan 4.7.1 Japan: Managing changes 4.7.2 Japan: Clinical evaluation requirements 4.7.3 Japan: Audit requirements 4.8 People’s Republic of China (PRC) 4.8.1 PRC: Managing changes <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 4.8.2 PRC: Clinical evaluation requirements <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 4.8.3 PRC: Audit requirements 4.9 Russia 4.9.1 Russia: Managing changes 4.9.2 Russia: Clinical evaluation requirements 4.9.3 Russia: Audit requirements 4.10 United States of America (USA) 4.10.1 USA: Managing changes <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 4.10.2 USA: Clinical evaluation requirements 4.10.3 USA: Audit requirements <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 5 Managing changes that can impact the DCP 5.1 General 5.2 Change evaluation 5.2.1 Identify changes <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 5.2.2 Risk evaluation 5.2.3 Guidance for change evaluation <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 5.2.4 Pre-market 5.3 Interactions with region-specific regulatory authorities \u2014 Post-commercialization <\/td>\n<\/tr>\n | ||||||
30<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" Cardiovascular implants and extracorporeal systems. Vascular device-drug combination products – Local regulatory information<\/b><\/p>\n |